Year: 2026
Type: review
Study design: Systematic Review
Abstract: Diabetes mellitus is one of the most important metabolic disorders associated with increased cardiovascular risk, mainly through acceleration of the atherothrombotic process and impaired platelet function.This systematic review examines the role of antithrombotic therapy in reducing cardiovascular events in patients with diabetes mellitus, as well as its safety in the light of bleeding risk.The theoretical background focuses on the pathophysiology of the prothrombotic phenomenon in diabetes, the high incidence of coronary artery disease, cerebrovascular accidents and peripheral arterial disease, as well as the importance of antithrombotic therapy as a central axis of prevention.The aim of the study was to investigate in depth the efficacy and safety of antithrombotic therapy, with emphasis on the balance between reducing ischemic events and causing bleeding complications.The methodology was based on a systematic review of the literature according to the PRISMA 2020 guidelines, with a search in the PubMed and Scopus databases, and the inclusion of randomized clinical trials, meta-analyses and large cohort studies of recent years.The results show that antithrombotic therapy significantly reduces major cardiovascular events, especially in high-risk patients, as demonstrated by studies such as PEGASUS, COMPASS and THEMIS.However, the intensification of therapy is accompanied by an increased bleeding risk, which limits the generalized application of potent combination regimens.In addition, significant heterogeneity in response is highlighted, which is related to glycemic control, insulin resistance, residual platelet reactivity, genetic factors and renal function.In conclusion, antithrombotic therapy in diabetes mellitus is a dynamic and individualized process, where the optimal balance between ischemic benefit and bleeding risk requires multivariate assessment.The transition to personalized therapeutic strategies with the integration of clinical, metabolic and genetic markers seems to be the future direction for optimizing cardiovascular prevention in this population.
Author: Μανές, Παναγιώτης Α.
Language: Greek
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: diabetes mellitus, antithrombotic therapy, cardiovascular risk, bleeding risk, platelet function, atherothrombosis, coronary artery disease, cerebrovascular disease, peripheral arterial disease, PEGASUS trial, COMPASS trial, personalized treatment, glycemic control, insulin resistance, genetic markers, renal function
Open Access status: green
OpenAlex ID: W7172477230
